A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I.
Tsuji D, Nakagaki S, Yonezawa I, Suzuki K, Yokokawa T, Kawasaki Y, Yamaguchi T, Kawaguchi T, Hatori M, Matsumoto T, Sakata Y, Yamamoto K, Nishimura T, Kogure Y, Hayashi T, Osawa M, Itoh K, Watanabe M.
Tsuji D, et al.
Invest New Drugs. 2024 Feb;42(1):44-52. doi: 10.1007/s10637-023-01414-y. Epub 2023 Dec 6.
Invest New Drugs. 2024.
PMID: 38055127
Clinical Trial.